Medibank Private Ltd (ASX: MPL) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Medibank Private Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Medibank Private Ltd (ASX: MPL)
Latest News
Healthcare Shares
Own Medibank shares? Here’s what to watch over the coming months
Dividend Investing
How big will the Medibank dividend be in 2022?
Broker Notes
The Medibank share price has leapt 5% in a month. Could it be on the comeback trail in May?
Healthcare Shares
This ASX 200 healthcare share has a fully franked dividend yield over 4% right now
Financial Shares
Why is the Medibank share price trailing NIB over the past year?
Share Fallers
Why did the Medibank share price go backwards in March?
Healthcare Shares
Why has the Medibank (ASX:MPL) share price lost 11% since early January?
Healthcare Shares
Own Medibank (ASX:MPL) shares? Now you own a piece of this tech start-up
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
04 Mar 2022 | $0.0610 | 100.00% | Interim | 24 Mar 2022 |
08 Sep 2021 | $0.0690 | 100.00% | Final | 30 Sep 2021 |
03 Mar 2021 | $0.0580 | 100.00% | Interim | 25 Mar 2021 |
02 Sep 2020 | $0.0630 | 100.00% | Final | 24 Sep 2020 |
03 Mar 2020 | $0.0570 | 100.00% | Interim | 26 Mar 2020 |
04 Sep 2019 | $0.0250 | 100.00% | 26 Sep 2019 | |
04 Sep 2019 | $0.0740 | 100.00% | Final | 26 Sep 2019 |
05 Mar 2019 | $0.0570 | 100.00% | Interim | 28 Mar 2019 |
05 Sep 2018 | $0.0720 | 100.00% | Final | 27 Sep 2018 |
06 Mar 2018 | $0.0550 | 100.00% | Interim | 28 Mar 2018 |
06 Sep 2017 | $0.0675 | 100.00% | Final | 28 Sep 2017 |
07 Mar 2017 | $0.0525 | 100.00% | Interim | 29 Mar 2017 |
06 Sep 2016 | $0.0600 | 100.00% | Final | 28 Sep 2016 |
04 Mar 2016 | $0.0500 | 100.00% | Interim | 29 Mar 2016 |
03 Sep 2015 | $0.0530 | 100.00% | 28 Sep 2015 |
MPL ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Medibank Private Ltd
Medibank Private Ltd (ASX: MPL) is an integrated healthcare company providing private health insurance and health solutions to 3.7 million Australians. Medibank’s core business is the underwriting and distribution of private health insurance policies – as well as travel, life and pet insurances – through its two brands, Medibank and AHM.
Medibank offers hospital cover and extras cover to customers in Australia as well as health insurance to overseas visitors and students. It also provides integrated healthcare services to policyholders, government, corporate and other customers. These include mental health support, preventative and better integrated primary care and after-hours health support.
Established as a not-for-profit private health insurer by the Australian government in 1976, Medibank was sold and listed on ASX in 2014. The Medibank share price peaked at $3.67 in July 2019.
MPL Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
13 May 2022 | $3.19 | $0.04 | 1.27% | 9,548,208 | $3.16 | $3.21 | $3.15 |
12 May 2022 | $3.15 | $-0.03 | -0.94% | 10,115,932 | $3.17 | $3.19 | $3.14 |
11 May 2022 | $3.18 | $-0.02 | -0.63% | 8,951,094 | $3.18 | $3.20 | $3.14 |
10 May 2022 | $3.20 | $-0.02 | -0.62% | 16,039,310 | $3.20 | $3.22 | $3.14 |
09 May 2022 | $3.22 | $-0.03 | -0.92% | 9,392,250 | $3.28 | $3.28 | $3.21 |
06 May 2022 | $3.25 | $0.03 | 0.93% | 13,041,065 | $3.20 | $3.25 | $3.18 |
05 May 2022 | $3.22 | $0.05 | 1.58% | 14,439,820 | $3.17 | $3.23 | $3.12 |
04 May 2022 | $3.17 | $-0.03 | -0.94% | 8,309,910 | $3.20 | $3.20 | $3.14 |
03 May 2022 | $3.20 | $0.02 | 0.63% | 7,860,535 | $3.20 | $3.20 | $3.15 |
02 May 2022 | $3.18 | $-0.02 | -0.63% | 7,221,956 | $3.17 | $3.22 | $3.17 |
29 Apr 2022 | $3.20 | $0.04 | 1.27% | 5,678,228 | $3.16 | $3.21 | $3.16 |
28 Apr 2022 | $3.16 | $0.02 | 0.64% | 4,342,276 | $3.13 | $3.16 | $3.11 |
27 Apr 2022 | $3.14 | $0.01 | 0.32% | 6,301,685 | $3.14 | $3.16 | $3.12 |
26 Apr 2022 | $3.13 | $-0.06 | -1.88% | 5,247,486 | $3.15 | $3.17 | $3.12 |
22 Apr 2022 | $3.19 | $-0.03 | -0.93% | 5,192,832 | $3.20 | $3.21 | $3.17 |
21 Apr 2022 | $3.22 | $0.00 | 0.00% | 5,679,279 | $3.25 | $3.25 | $3.19 |
20 Apr 2022 | $3.22 | $0.05 | 1.58% | 9,930,241 | $3.24 | $3.25 | $3.20 |
19 Apr 2022 | $3.17 | $0.03 | 0.96% | 7,436,023 | $3.13 | $3.19 | $3.12 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
22 Mar 2022 | Gerard Dalbosco | Buy | 48 | $150,524 | On-market trade. average price per share |
03 Dec 2021 | David Koczkar | Issued | 821 | $2,785,346 | Issue of securities. 1,208,604 - Performance Rights |
08 Nov 2021 | David Koczkar | Transfer | 65 | $225,055 | As advised by the company. Transfer of 65,045 Ordinary Shares from David Koczkar to Olive Man Investments Pty Ltd |
08 Nov 2021 | David Koczkar | Transfer | 65 | $225,055 | As advised by the company. Transfer of 65,045 Ordinary Shares from David Koczkar to Olive Man Investments Pty Ltd |
27 Aug 2021 | David Koczkar | Exercise | 65 | $229,608 | Conversion of securities. 525,187 - Performance Rights |
27 Aug 2021 | David Koczkar | Buy | 65 | $229,608 | Conversion of securities. |
27 Aug 2021 | David Koczkar | Expiry | 138 | $487,913 | As advised by the company. 386,968 - Performance Rights 138,219 lapsed Performance Rights |
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Michael (Mike) John Wilkins | Non-Executive DirectorNon-Executive Chairman | May 2017 | Mr Wilkins has more than 30 years of experience in financial services, predominantly in Australia and Asia. He served as Managing Director and Chief Executive Officer at Insurance Australia Group (November 2007 to November 2015), Managing Director and Chief Executive Officer at Promina Group Limited and Managing Director at Tyndall Australia Limited. He also served as Acting Chief Executive Officer (April 2018 to December 2018), Executive Chairman (April 2018 to June 2018) and a director (September 2016 to February 2020) of AMP Limited. He was previously a director of Maple-Brown Abbott Limited, Alinta Limited, The Geneva Association and the Australian Business and Community Network. He is a member of the Investment, and Capital and the People Committee. |
Mrs Linda Bardo Nicholls | Non-Executive Director | Mar 2014 | Mrs Nicholls has more than 30 years of experience as a senior executive and director in banking, insurance and funds management in Australia, New Zealand and the United States. She is currently Chairman of Japara Healthcare Limited (since March 2014) and a director of Inghams Group Limited (since November 2016). Linda is also Chairman of the Board of Melbourne Health and a member of the Museums Board of Victoria. Linda's previous directorships include Fairfax Media Limited (February 2010 to December 2018), Pacific Brands Limited (October 2013 to July 2016), Sigma Pharmaceuticals Limited (December 2005 to December 2015) and Healthscope Limited, as Chairman (October 2008 to October 2010) and a director (January 2000 to October 2010). She is Chairman of the People committee. |
Ms Kathryn Joy Fagg | Non-Executive Director | Mar 2022 | Ms Fagg is a director and Chair with senior commercial and operational experience. Ms Fagg is currently a director of National Australia Bank Ltd (since December 2019) and Djerriwarrh Investments Ltd (since May 2014). She is also the Chair of CSIRO, Watertrust Australia Ltd and Breast Cancer Network Australia, and a director of The Myer Foundation, the Grattan Institute and the Champions of Change Coalition. She has previously been Chair (July 2018-July 2021) and a director (September 2014-July 2021) of Boral Ltd and a director of Incitec Pivot Ltd (April 2014-December 2019). She is a former President of Chief Executive Women and a former board member of the Reserve Bank of Australia, and held senior executive roles at Linfox, Bluescope Steel and ANZ. |
Mr David Fagan | Non-Executive Director | Mar 2014 | Mr Fagan held a variety of positions at Clayton Utz culminating in the role of Chief Executive Partner for nine years. In this role, David had responsibility and accountability for transformation, strategy, finance, stakeholder engagement, and governance, including risk management. During David's tenure as Chief Executive Partner, Clayton Utz entrenched itself as a first class top tier commercial law firm. David also chaired the Medibank Privatisation Committee which operated during 2014 in preparation for the privatisation process. David is a former director and Chair of the Audit Committee of The Global Foundation, a former director of Grocon Funds Management Group, the Hilco Group and UBS Grocon Real Estate Investment Management Australia Pty Limited and a former member of the advisory board of Chase Corporate Advisory. David is currently a director of PayGroup Limited (since November 2017). He is Chair of BDO Group Holdings Limited and a member of the ASIC Corporate Governance Consultative Panel. He is Chairman of the Risk Management Committee and a member of the Investment and Capital Committee. |
Ms Anna Bligh | Non-Executive Director | Dec 2014 | Ms Bligh has experience in the fields of healthcare, finance, infrastructure and project management. She has held several roles in the Queensland Government, including Premier, Treasurer, Minister for Finance, Minister for State Development, Minister for Trade and Innovation and Minister for Education. She was also a member of the Queensland Cabinet Budget Review Committee for 11 years. Anna was a director of Bangarra Dance Theatre Australia (2012-2020) and is currently a non-executive director of Australian Plays Transform. She is a member of the Investment and Capital and the People Committee. |
Mr David Koczkar | Chief Executive OfficerManaging Director | May 2021 | Mr Koczkar has more than 25 years of strategy, customer and commercial experience, including previous work in the strategy consulting and financial services industries. Prior to joining Medibank, David was the Group Chief Commercial Officer at Jetstar where he was responsible for the airline group's network management, sales and marketing, customer channels and commercial operations, including as a director of Jetstar Pacific (Vietnam), Jetstar Hong Kong and NewStar (Singapore) JV businesses. |
Mr Peter Dobie Everingham | Non-Executive Director | Mar 2022 | Mr Everingham has over 25 years corporate experience and is respected in the digital sector, having held senior executive roles in that sector for 18 years. His senior leadership experience includes roles at companies with a consumer and technology focus. Mr Everingham is currently a director of Super Retail Group Limited (since December 2017), the owner of several notable Australian brands including BCF, Macpac, Rebel and Supercheap Auto. He is also a director of iCar Asia Limited (since July 2017) and WWF Australia. He was previously Managing Director of the international division of Seek Limited (and concurrently Chair of Seeks subsidiary, Zhaopin), a director of ME Bank and IDP Education Ltd, and a senior executive for Yahoo! In Australia and Southeast Asia. |
Dr Tracey Batten | Non-Executive Director | Aug 2017 | Dr Batten has experience in the health services sector, with commercial, business and change skills. Tracey is currently a director of EBOS Group Limited (since July 2021), the National Institute of Water and Atmospheric Research in New Zealand and the New Zealand Accident Compensation Corporation, and a former director of Abano Healthcare Group. Tracey was previously the Chief Executive of the Imperial College Healthcare NHS Trust in the United Kingdom. In that role, Tracey focused on change leadership, in particular improving organisational culture and strengthening patient safety and experience. Tracey also oversaw the implementation of a range of digital initiatives as Chief Executive. Tracey is a former Chief Executive of St Vincent's Health Australia, which runs a group of public hospitals, private hospitals and aged care facilities. She is a member of the Risk Management and the People committee. |
Mr Gerard Dalbosco | Non-Executive Director | May 2021 | Mr Dalbosco held a number of senior roles as a Partner of EY until September 2020. His most recent role was Melbourne Managing Partner where he led a large team responsible for EYs go-to-market and client service strategies. Prior to this, Gerard held other roles at EY including Asia Pacific Managing Partner -Markets and Co-Deputy CEO where he led EYs client-serving activities across the Asia Pacific market. He was also Oceania Managing Partner and CEO, and Oceania Managing Partner of Transaction Advisory Services where he was responsible for EYs Transaction Advisory Services business across Oceania. Gerard is currently Chair of Melbourne Archdiocese Catholic Schools and Co-Deputy Chair and Chair of the Finance Committee of the Committee for Melbourne. He has previously held roles as a director and Chair of the Finance & Audit Committee of Mercy Health & Aged Care, director and member of the Finance Committee of Berry Street Victoria, and Chair of the National Gallery of Victoria's Business Council. He is a member of the Risk Management Committee. |
Ms Mei Ramsay | Group General CounselCompany Secretary | Mar 2011 | - |
Mark Rogers | Group Executive - Chief Financial Officer & Group Strategy | - | |
Dr Andrew Wilson | Group Executive - CEO Health Services | - | |
Rob Deeming | Group Executive - Customer & Brands | - | |
Milosh Milisavljevic | Group Executive - Customer Portfolios | - | |
Kylie Bishop | Group Executive - People & Culture | - | |
John Goodall | Group Executive - Technology & Operations | - | |
Mei Ramsay | Group General CounselCompany Secretary | - |
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
HSBC Custody Nominees (Australia) Limited | 844,196,960 | 30.65% |
J P Morgan Nominees Australia Pty Limited | 515,398,135 | 18.71% |
Citicorp Nominees Pty Limited | 269,831,924 | 9.80% |
National Nominees Limited | 144,394,624 | 5.24% |
BNP Paribas Nominees Pty Ltd <Agency Lending Drp A/C> | 64,160,779 | 2.33% |
BNP Paribas Noms Pty Ltd <Drp> | 52,703,501 | 1.91% |
HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/ | 23,213,664 | 0.84% |
BNP Paribas Nominees Pty Ltd Six Sis Ltd <Drp A/C> | 20,179,643 | 0.73% |
Citicorp Nominees Pty Limited <Colonial First State Inv A/C> | 13,969,892 | 0.51% |
Netwealth Investments Limited <Wrap Services A/C> | 6,541,236 | 0.24% |
The Senior Master Of The Supreme Court <Common Fund No 3 A/C> | 6,500,000 | 0.24% |
Navigator Australia Ltd <Sma Antares Inv Dv Build A/C> | 6,150,413 | 0.22% |
Australian Executor Trustees Limited <IPS Super A/c> | 6,054,833 | 0.22% |
BNP Paribas Nominees Pty Ltd Acf Clearstream | 5,412,538 | 0.20% |
BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <Drp A/C> | 5,267,074 | 0.19% |
Netwealth Investments Limited <Super Services A/C> | 3,609,344 | 0.13% |
BNP Paribas Noms Pty Ltd <Arbitage Snc Drp> | 3,433,369 | 0.12% |
National Nominees Limited <Db A/C> | 3,413,056 | 0.12% |
Neweconomy Com Au Nominees Pty Limited <900 Account> | 3,322,276 | 0.12% |
AMP Life Limited | 3,013,952 | 0.11% |